Simulations Plus, Inc.

Equities

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
48.62 ^USD	+1.55%		+0.98%	+8.65%

28/06	William Blair Initiates Simulations Plus at Outperform	MT
13/06	Craig-Hallum Raises Price Target on Simulations Plus to $56 From $51, Maintains Buy Rating	MT

Simulations Plus, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019

January 10, 2020 at 02:35 am IST

Simulations Plus, Inc. announced earnings results for the first quarter ended November 30, 2019. For the first quarter, the company announced sales was USD 9.401 million compared to USD 7.535 million a year ago. Operating income was USD 2.718 million compared to USD 2.086 million a year ago. Net income was USD 2.058 million compared to USD 1.535 million a year ago. Basic earnings per share from continuing operations was USD 0.12 compared to USD 0.09 a year ago. Diluted earnings per share from continuing operations was USD 0.11 compared to USD 0.09 a year ago.

Latest news about Simulations Plus, Inc.

William Blair Initiates Simulations Plus at Outperform	28/06	MT
Craig-Hallum Raises Price Target on Simulations Plus to $56 From $51, Maintains Buy Rating	13/06	MT
Oppenheimer Adjusts Price Target on Simulations Plus to $65 From $55, Maintains Outperform Rating	13/06	MT
Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal Year 2024	13/06	CI
Simulations Plus Seeks Acquisitions	13/06	CI
Transcript : Pro-Ficiency Holdings, Inc., Simulations Plus, Inc. - M&A Call	13/06
Simulations Plus Acquires Pro-ficiency For $100 Million	12/06	MT
Simulations Plus, Inc. acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency?s minority shareholders for approximately $100 million.	12/06	CI
Simulations Plus, Inc. acquired Pro-Ficiency Holdings, Inc. from QHP Capital, L.P. and others for $100 million.	12/06	CI
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software	15/05	CI
Simulations Plus Insider Sold Shares Worth $918,984, According to a Recent SEC Filing	03/05	MT
InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance	17/04	CI
Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023.	05/04	CI
Sector Update: Health Care Stocks Slump Late Afternoon	05/04	MT
Simulations Plus Says FDA Renews DILIsym Software Licenses	04/04	MT
Sector Update: Tech Stocks Advance Premarket Thursday	04/04	MT
Simulations Plus, Inc. Announces U.S. FDA Renews DILIsym Software Licenses	04/04	CI
Sector Update: Tech	04/04	MT
Simulations Plus Fiscal Q2 Earnings Beat as Revenue Rises; Maintains Full-Year Outlook; Shares Advance Premarket	04/04	MT
Simulations Plus Fiscal Q2 Net Income Is Unchanged, Revenue Rises; FY Outlook Maintained; Shares Jump After Hours	04/04	MT
Simulations Plus to Seek M&A	04/04	CI
Transcript : Simulations Plus, Inc., Q2 2024 Earnings Call, Apr 03, 2024	04/04
(SLP) SIMULATIONS PLUS Expects Fiscal Year 2024 EPS Range $0.66 - $0.68	04/04	MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 Revenue $18.3M, vs. Street Est of $17.3M	04/04	MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 EPS $0.20, vs. Street Est of $0.18	04/04	MT

Chart Simulations Plus, Inc.

Duration

Period

More charts

Company Profile

Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.

Sector

Advanced Medical Equipment & Technology

Calendar

02/07/2024 - Q3 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Simulations Plus, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

48.62 USD

Average target price

60.33 USD

Spread / Average Target

+24.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
SIMULATIONS PLUS, INC.	+8.65%	96Cr
VEEVA SYSTEMS INC.	-4.94%	2.99TCr
PRO MEDICUS LIMITED	+49.49%	969.95Cr
SECTRA AB	+34.36%	442.46Cr
EVOLENT HEALTH, INC.	-42.11%	230.04Cr
VERADIGM INC.	-9.44%	151.95Cr
OMNICELL, INC.	-28.06%	120.64Cr
LUNIT INC.	-42.92%	97Cr
B-SOFT CO.,LTD.	-47.18%	75Cr
ENTERO HEALTHCARE SOLUTIONS LIMITED	0.00%	55Cr

Medical Software & Technology Services